Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on November 17, 2014. The report discloses a material event regarding the presentation of clinical trial data for the company's investigational drug, NSI-189, in the treatment of Major Depressive Disorder.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance.
Material Changes
The primary material event reported is the presentation of Phase IB clinical trial data for NSI-189 at the CNS Summit in Boca Raton, FL, on November 14, 2014. No financial changes versus prior periods are detailed in this document.
Outlook, Risks, and Management Commentary
Management highlighted the dissemination of clinical data as a significant milestone. The filing references a press release (Exhibit 99.01) for further details on the trial results. No specific forward-looking guidance, risk factors, or contingencies are explicitly detailed within the body of this 8-K form.
Investor Verification Checklist
- Verify the specific clinical outcomes and statistical significance of the NSI-189 Phase IB trial data presented at the CNS Summit.
- Review the attached press release (Exhibit 99.01) for detailed commentary on the trial results.
- Confirm the regulatory status and future development timeline for NSI-189 following this data presentation.
- Check subsequent filings for any financial impact or capital requirements related to advancing the clinical program.